The pneumonia vaccine trains your immune system to recognize and fight Streptococcus pneumoniae, the bacterium responsible for most cases of bacterial pneumonia as well as serious infections like meningitis and bloodstream infections. It doesn’t contain live bacteria. Instead, it uses pieces of the bacterial outer shell to teach your body to produce antibodies, so if you’re ever exposed to the real thing, your immune system can respond quickly before the infection takes hold.
How the Vaccine Triggers Immunity
Pneumococcal bacteria are surrounded by a sugar-based capsule that helps them evade your immune system. The vaccine works by exposing your body to fragments of that capsule, prompting it to build antibodies that can recognize and neutralize the bacteria later. But the type of vaccine matters for how strong and lasting that response is.
The older polysaccharide vaccine (PPSV23) presents sugar fragments on their own. Your immune system can respond to these, but it’s a relatively weak reaction because your T cells, the immune cells that help create long-term memory, aren’t directly involved. This means the protection it provides tends to fade faster and doesn’t work well in young children, whose immune systems haven’t matured enough to respond to sugar-only signals.
The newer conjugate vaccines solve this problem by chemically attaching those sugar fragments to a protein carrier. When immune cells process this combination, they present the sugar-protein package to specialized helper T cells, which then activate B cells in your lymph nodes. This T cell-dependent response produces stronger antibodies and, crucially, creates immune memory cells that stick around for years. It’s the same principle behind vaccines for other encapsulated bacteria like those that cause certain types of meningitis.
What It Protects Against
The vaccine’s primary job is preventing invasive pneumococcal disease: infections where the bacteria enter parts of the body that are normally sterile, like the blood, the fluid around the brain, or the lungs. These include bacterial pneumonia, bacteremia (bacteria in the bloodstream), and meningitis. Pneumococcal meningitis is particularly dangerous, with a case fatality rate of 17.5% overall and nearly 32% among adults over 65. About a third of survivors experience long-term neurological problems.
Population-level data from England and Wales shows the impact clearly. After the 13-strain conjugate vaccine replaced the earlier 7-strain version in childhood immunization programs, pneumococcal meningitis rates dropped 48%. In Ontario, pneumonia hospitalization rates fell 27% to 47% across different elderly age groups after childhood conjugate vaccination programs were introduced, even though those older adults weren’t the ones being vaccinated directly. This indirect protection happens because vaccinated children stop carrying and spreading the bacteria to vulnerable adults.
For adults 65 and older who receive the 20-strain conjugate vaccine directly, real-world data shows it prevents roughly 25.6% of all invasive pneumococcal disease cases, with stronger protection in the 65-to-74 age group (35.4%) than in those 85 and older (16.6%). The vaccine also prevented an estimated 262 cases of pneumonia per 100,000 person-years in adults over 65.
Types of Pneumonia Vaccines Available
Four pneumococcal vaccines are currently available in the United States, and they differ in how many bacterial strains they cover and how they work:
- PCV15 (Vaxneuvance): A conjugate vaccine covering 15 strains
- PCV20 (Prevnar 20): A conjugate vaccine covering 20 strains
- PCV21 (Capvaxive): A conjugate vaccine covering 21 strains
- PPSV23 (Pneumovax 23): A polysaccharide vaccine covering 23 strains
Although PPSV23 covers the most strains, the conjugate vaccines produce a stronger and longer-lasting immune response. Current guidelines favor conjugate vaccines for most people, sometimes followed by PPSV23 to broaden coverage.
Who Should Get It
The CDC recommends the pneumonia vaccine for two main groups: all children under 5 and all adults 50 and older. Children receive a series of doses starting in infancy as part of their routine vaccination schedule.
Adults and children outside those age ranges may also need it if they have conditions that raise their risk of severe pneumococcal infection. These include immunocompromising conditions (like HIV, organ transplants, or certain cancers), cochlear implants, and cerebrospinal fluid leaks. For people with weakened immune systems, the minimum wait between vaccine doses can be shortened to 8 weeks rather than the standard longer intervals.
How Long Protection Lasts
Immunity develops about two to three weeks after vaccination and generally lasts around five years, though children and elderly adults may need earlier revaccination. The conjugate vaccines tend to provide more durable protection than the polysaccharide vaccine because of the stronger immune memory they create.
If you’ve previously received an older pneumococcal vaccine, you may benefit from an updated one. For example, adults who received only the 13-strain conjugate vaccine can get a 20-strain version at least one year later for broader protection. Those who’ve had the polysaccharide vaccine alone can receive a conjugate vaccine at least one year afterward. The specifics depend on which vaccines you’ve already had and your age, so your vaccination history matters when determining next steps.
Common Side Effects
The most frequent side effect is soreness at the injection site, reported by about 56% of recipients. This is typical of most vaccines and usually resolves within a day or two. Systemic reactions are less common: fatigue affects roughly 27% of people, headache about 18%, and muscle aches around 11%. High fevers of 104°F or above occurred in only 0.1% of clinical trial participants and resolved on their own. Serious adverse events are rare.